Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ketorolac eye drops
ketorolac eye · 1 trial · 1 indication
Anterior chamber inflammation is the sum of biomicroscopic cell and flare; each measured on a scale of 0-4 (Flare: 0 = no flare, 4 = intense flare / Cell: 0 = no cells, 4 = \>50 cells)
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ketorolac eye drops | DRUG | 1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day Placebo |
Inclusion Criteria: * Patients undergoing cataract surgery Exclusion Criteria: * Uncontrolled ocular disease in cataract surgery eye
Ketorolac eye is an ophthalmic small molecule being developed for cataract extraction, specifically to treat the inflammation and pain associated with cataract surgery. It is a topical eye drop formulation. The program is in Phase 3 development, and the single registered trial in this program has been completed.
Ketorolac eye targets PTGS2 and PTGS1, also known as cyclooxygenase-2 and cyclooxygenase-1. It acts as an inhibitor of these enzymes. By inhibiting PTGS1 and PTGS2, ketorolac reduces prostaglandin synthesis, which is the mechanism behind its anti-inflammatory and analgesic activity in the eye.
Ketorolac eye drops are being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the Phase 3 program evaluating the ophthalmic formulation in cataract extraction.
Ketorolac eye is in Phase 3 development. It is an investigational ophthalmic product and is not described as approved. The program has one registered trial, which is completed, with no trials currently listed as active.
Ketorolac eye has been studied in one registered trial, NCT00521456, titled A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery. It was a Phase 3, randomized, double-blind, placebo-controlled trial that enrolled 263 participants in the United States and is completed.
Yes. Ketorolac eye and ketorolac eye drops refer to the same ophthalmic product. Ketorolac eye drops is simply the alternative name used for this topical formulation, which is being developed by AbbVie for inflammation and pain associated with cataract extraction.